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BRIEF DEFINITIVE REPORT
           Atherosclerosis is a disease of the vasculature 
that is characterized by chronic infl  ammation of 
the arterial wall (  1  ). The vessel is infi  ltrated by 
macrophages and T cells, which, together with 
resident smooth muscle and endothelial cells 
(ECs), produce cytokines, growth factors, and 
other proinfl  ammatory mediators in response to 
the presence of oxidized low-density lipoprotein 
(ox-LDL). B cells are rarely found in plaques, 
although patients do exhibit a systemic antibody 
response to ox-LDL (  2  ), and B cells have been 
shown to be protective against atherosclerosis in 
murine models (  3, 4  ). The majority of T cells 
present in human atherosclerotic plaques are of 
the CD4  +   subset and predominantly produce 
cytokines of the Th1 subtype, such as IFN     (  5  ). 
Furthermore, a critical pathogenic role for Th1 
cells has been shown in murine atherosclerosis 
models (  6  –  10  ). 
  In contrast, most studies have demonstrated 
an atheroprotective eff  ect of Th2 cells, with the 
exception of IL-4, which has produced con-
fl  icting results (  1, 7  ). Recent work has estab-
lished that defi  ciency of the Th2 cytokine IL-5 
reduced the production of atheroprotective ox-
LDL antibodies and accelerated atherosclerosis 
in ApoE      /      mice (  11  ). Therefore, it is postulated 
that a Th1-to-Th2 switch may attenuate athero-
sclerosis development. However, the mechanism 
with which to accomplish such a switch in vivo 
remains obscure. We now demonstrate that the 
most recently identifi  ed cytokine, IL-33, can 
  induce a Th1-to-Th2 shift in vivo in an ApoE      /      
model of atherosclerosis. 
  IL-33 is a recently described member of the 
IL-1 family, which includes IL-1     and -18. Like 
IL-1     and -18, IL-33 was found to have strong 
immunomodulatory functions (  12  ). However, 
unlike IL-1     and -18, which mainly promote 
Th1-associated responses, IL-33 predominantly 
induces the production of Th2 cytokines (IL-5 
and -13) and increases levels of serum immuno-
globulin. IL-33 was recently found to be the 
  ligand for the orphan receptor ST2 (  12  ). The ST2 
gene encodes two isoforms of ST2 protein: ST2L, 
a transmembrane form, and soluble ST2 (sST2), 
a secreted form that can serve as a decoy re-
ceptor of IL-33. ST2L is preferentially expressed 
on Th2 cells, but not Th1 cells (  13  ), and can pro-
foundly suppress innate and adaptive immunity. 
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P   <   0.0001;   Fig. 2, A and B  ).   However, IL-33 treatment re-
duced the percentage of plaque area that stained positive for 
F4/80  +   macrophages (16.2   ±   3.9 vs. 50.3   ±   7.8; P   <   0.05; 
  Fig. 2, C and D  ) and reduced the number of lesion-associated 
CD3  +   T lymphocytes (2,710   ±   363 vs. 4,665   ±   821 cells/mm  2  ; 
P   <   0.05;   Fig. 2, C and D  ). Plaque stability is critically de-
pendent on the SMC and collagen content of the fi  brous cap. 
Therefore, we performed     -smooth muscle actin (brown) and 
trichrome collagen staining (blue) of plaques and found simi-
lar staining between the PBS- and IL-33  –  treated mice (31.6   ±   
3.1 vs. 35.2   ±   6.3% and 22.3   ±   2.1 vs. 26.6   ±   2.7%, respec-
tively;   Fig. 2, C and D  ), indicating that IL-33 has reduced 
plaque size without adversely aff  ecting SMC or collagen con-
tent. IL-33 also did not aff  ect the fi  nal body weight of the 
mice (PBS-treated, 30.8   ±   0.8 g vs. IL-33  –  treated, 30.6   ±   0.9 g), 
ST2L is also expressed in cardiomyocytes, and serum elevations 
of sST2 predict mortality and heart failure in patients with 
acute myocardial infarction (  14, 15  ). Recently, it was shown that 
IL-33/ST2 signaling is a crucial biomechanically activated 
system that controlled cardiomyocyte hypertrophy and cardiac 
fi  brosis after pressure overload (  16  ). However, the role of IL-
33/ST2 in atherosclerosis has not been investigated. We now 
show that IL-33 administration to ApoE      /      mice induced 
Th2 cytokines and protective ox-LDL antibodies, which sig-
nifi  cantly reduced atherosclerotic plaque development in the 
aortic sinus. Conversely, mice treated with sST2 developed 
signifi  cantly larger atherosclerotic plaques in the aortic sinus. 
These results demonstrate a novel role for IL-33/ST2 in the 
control of Th1/Th2 balance and the generation of protective 
autoantibodies in atherosclerosis. 
    RESULTS AND DISCUSSION   
  IL-33 and ST2 are expressed in vascular cells and tissues 
  It has been reported that smooth muscle cells (SMCs) and 
ECs can produce or respond to IL-1 and -18 (  17  ). Recently, 
RT-PCR analysis of human and mouse cDNA libraries re-
vealed the expression of IL-33 mRNA in dermal fi  broblasts, 
keratinocytes, and coronary artery, bronchial, and pulmonary 
SMCs (  12  ). IL-33 is also expressed in ECs from chronically 
infl  amed rheumatoid arthritis synovium and Crohn  ’  s disease 
intestine (  18  ). However, the expression of IL-33 in athero-
sclerotic tissues has not been previously investigated. 
  We examined the expression of IL-33 and its receptor 
ST2 in murine and human vascular cells and tissues by PCR 
and immunohistochemistry. IL-33 and ST2 mRNA was 
  present in the thoracic aorta of 18-wk-old C57BL/6 control 
mice (normal diet) and ApoE      /      (normal diet or high-fat diet) 
mice (  Fig. 1 A  ) and in primary cultured human ECs and SMCs 
(  Fig. 1 B  ). Quantitative PCR demonstrated a signifi  cantly 
higher expression of the IL-33 gene in aortas from ApoE      /      
mice fed a high-fat diet versus controls (  Fig. 1 C  ). Expression of 
IL-33 was also demonstrated by immunostaining in arteries and 
small vessels (  Fig. 1, D and E  ). Staining of parallel sections 
showed a similar pattern of the IL-33 expression with an 
    -smooth muscle actin stain in the adventitia of larger vessels, 
but not in the media, and the endothelial-specifi  c marker CD31 
in small arteries (  Fig. 1, D and E  ). The presence of IL-33 in the 
normal and atherosclerotic vasculature suggests its potential as 
a regulator of atherosclerosis under physiological or patho-
physiological conditions. 
  IL-33 reduces atherosclerosis development in ApoE       /       mice 
  6-wk-old male ApoE      /      mice were fed a high-fat diet (0.15% 
cholesterol and 21% lard) for 12 wk. During the last 6 wk, 
the mice were injected i.p. twice per week with PBS or re-
combinant IL-33 (1   μ  g/injection). Mice were killed at the end 
of the treatment, and intimal atherosclerotic lesion size was 
quantifi  ed in the aortic sinus by computerized planimetry. 
Mice treated with IL-33 developed a substantially smaller 
athero  sclerotic lesion size in the aortic sinus compared with 
PBS-treated control mice (0.16   ±   0.02 vs. 0.42   ±   0.04 mm  2  ; 
    Figure 1.     Expression of IL-33 and ST2 in vascular cells and tissues. 
  The expression of mRNAs for IL-33, ST2, and     -actin were examined by 
RT-PCR in the thoracic aortas of 18-wk-old C57BL/6 control mice (normal 
diet) or ApoE     /     (normal diet or high-fat diet) mice (A;   n   = 3) and in pri-
mary cultured human umbilical vein ECs (HUVECs), human saphenous 
vein ECs (HSVECs), human saphenous vein SMCs (HSVSMCs), and human 
coronary artery SMCs (HCASMCs; B). (C) Quantitative PCR analysis of IL-33 
gene expression in thoracic aortas of mice as described in A (expressed as 
a percentage of 18S endogenous control;   n   = 4  –  5). Data are the mean   ±   
the SEM. Immunostaining and isotype controls in frozen vascular tissues 
of ApoE     /     mice for     -smooth muscle actin and IL-33 in the adventitia of 
the aorta (D), and for CD31 and IL-33 in ECs of small vessels of the heart (E). 
A, adventitia; M, media; L, lumen. Images shown are representative of 
seven sections. *, P   <   0.05, Student  ’  s unpaired   t   test. Bars, 25    m.   JEM VOL. 205, February 18, 2008  341
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the level of ST2 expression, which is known to be expressed 
on Th2 cells, but not Th1 cells (  13, 19  ). Flow cytometric anal-
ysis of lymph node cells demonstrated that IL-33 treatment in-
duced a signifi  cantly higher percentage of ST2  +  CD4  +   cells 
compared with controls (3.6   ±   0.2 vs. 1.9   ±   0.6%; P   <   0.05). 
To examine their cytokine secretion profi  le, lymph node cells 
were cultured in vitro with anti-CD3 antibody and culture 
  supernatants examined by ELISA. Supernatants derived from 
IL-33  –  treated mice showed signifi  cantly elevated concentrations 
of IL-5 and -13, and markedly reduced IFN     compared with the 
supernatants of cells from control mice treated with PBS (  Fig. 
3 A  ).   IL-4 levels were low and not signifi  cantly diff  erent. 
  Recently, IL-17 was reported to be increased in plasma of 
unstable angina and acute myocardial infarction patients (  20  ), 
suggesting a potential role for this cytokine in coronary ath-
erosclerosis. Therefore, we examined IL-17 production in our 
model. Similar levels of IL-17 were produced by lymph node 
cells from both groups of mice (PBS-treated, 380   ±   117 vs. 
IL-33  –  treated, 441   ±   73 pg/ml), and IL-17 was below the limit 
of detection in serum by Luminex, thus indicating that Th17 
cells were not induced by IL-33. 
total serum cholesterol (23.6   ±   2.7 vs. 19.9   ±   1.9 mmol/liter), 
HDL-c (2.3   ±   0.2 vs. 2.1   ±   0.1 mmol/liter), very (V) LDL/
LDL-c (14.6   ±   2.4 vs. 15.4   ±   2.2 mmol/liter), or triglyceride 
(1.5   ±   0.2 vs. 1.3   ±   0.2 mmol/liter) concentrations. It is 
therefore unlikely that changes in lipoprotein levels account 
for the decreased lesion size. Schmitz et al. have demonstrated 
vascular changes in medium and small arteries of lung in mice 
treated with 0.4     g IL-33 protein i.p. daily for 7 d (  12  ). Histo-
logical analysis of all organs in mice at the end of this study 
demonstrated some lung vascular changes (mild medial hyper-
trophy) in only 1/12 mice. Hence, treatment with IL-33 did not 
appear to consistently induce lung pathological changes in our 
model. Overall, these results demonstrate that IL-33 eff  ectively 
reduces the development of atherosclerotic plaques in the 
ApoE      /      model of atherosclerosis. 
  Treatment with IL-33 induces Th2 cytokines in serum
and lymph node cells of ApoE       /       mice 
  The immunological profi  le of the ApoE      /      mice treated with 
IL-33 was investigated by assessing cytokine production by 
lymph node cells in vitro and in serum ex vivo. First, we assessed 
    Figure 2.     IL-33 treatment reduced atherosclerotic plaque size and macrophage and T cell accumulation in the aortic sinus of ApoE       /       mice.    
ApoE     /     mice were treated with PBS (open bars) or IL-33 (fi  lled bars). (A) Plaque size (intimal area, mm  2  ) in the aortic sinus (  n   =  12 – 15).  (B)  Representa-
tive photomicrographs of hematoxylin and eosin  –  stained aortic sections. (C) Quantifi  cation of plaque content: F4/80  +   macrophages (percentage of total 
plaque area;   n   = 11  –  12), T cells (number of CD3  +   T  cells/millimeter 2 ,   n   = 10  –  11), SMCs (percentage of total plaque area,   n   = 9  –  10), and collagen (percent-
age of total plaque area,   n   = 9  –  10). Data are the mean   ±   the SEM. (D) Representative photomicrographs of F4/80  +   macrophages (brown), CD3  +   T  cells 
(brown),     -smooth muscle actin (brown), and collagen (blue) staining in plaques of ApoE     /     mice treated with PBS or IL-33. Data shown are from two 
independent experiments. *, P   <   0.05; ***, P   <   0.001, Student  ’  s unpaired   t   test. Bars: (B) 400     m; (D; F4/80  +   macrophages) 25     m; (D; CD3  +   T cells) 25    m; 
(D;     -smooth muscle actin) 100     m; (D; collagen) 100    m.   342 IL-33 REDUCES ATHEROSCLEROSIS IN MICE | Miller et al.
mice (  12  ), suggesting that IL-6 may not play an important 
role in this model of atherosclerosis. Our data, however, are 
consistent with two other recent reports demonstrating that 
ApoE      /     xIL-6      /      mice developed larger atherosclerotic le-
sion than IL-6 intact ApoE      /      mice (  21  ) and that treatment 
with recombinant IL-6 resulted in smaller plaque lesions in 
ApoE      /      mice (  22  ). The absence of IL-10 may suggest that 
IL-33 treatment did not invoke a role for regulatory T cells, 
which have recently been shown to be protective against mouse 
atherosclerosis (  23  ). 
  Ox-LDL  –  specifi  c antibodies are induced in serum
of ApoE       /       mice by IL-33 treatment 
  Atherosclerosis is associated with antibody formation to oxi-
datively modifi  ed LDL, and elevated levels of this antibody 
predict regression of atherosclerosis in humans (  2  ). We assessed 
the humoral response to IL-33 treatment by quantifying anti-
body titers in serum. Th1 cells induce IgG  2a   production, whereas 
  Intracellular cytokine staining in CD4  +   lymph node cells 
demonstrated an increase in the percentage of IL-4  +   and -5  +   cells 
and a decrease in the percentage of IFN      +   cells in IL-33  –
  treated mice (  Fig. 3 B  ). These results were paralleled in serum 
where Luminex analysis demonstrated that IL-33  –  treated 
mice produced markedly more IL-4, -5, -6, and -13, but no 
detectable IFN     (  Fig. 3 C  ). Levels of other cytokines (IL-1    , 
-2, -10, -12[p70], TNF    , and MCP-1) in serum were low or 
absent. These results are consistent with a switch from a Th1 
to a Th2 immunological profi  le. Although the molecular 
mechanism by which IL-33 shifts the balance between Th1 
and Th2 cells is currently unknown and is being addressed, it 
likely involves a direct expansion of a subset of peripheral 
ST2  +   T cells. 
  IL-33 treatment also enhanced IL-6 synthesis, but not 
IL-10 production. Although IL-6 is generally regarded as a 
proinfl  ammatory cytokine, IL-6  –  defi  cient LDLR      /      mice had 
similar atherosclerotic lesions, as the IL-6 –  suffi   cient LDLR      /      
    Figure 3.     IL-33 induced Th2 cytokines, Th2 antibodies, and ox-LDL  –  specifi  c antibodies in serum and lymph node cells of ApoE       /       mice. 
   ApoE    /     mice were treated with PBS (open bars) or IL-33 (fi  lled bars). (A) Cytokine production (IL-4, -5, -13, and IFN    ) by lymph node cells restimulated 
with     CD3 and measured by ELISA. (B) Intracellular cytokine staining (IL-4, -5, and IFN    ) in CD4  +   lymph node cells stimulated with PMA/ionomycin for 4 h. 
Numbers indicate the percentage of positive cells in each quadrant. (C) IL-4, -5, -6, -13 (all picogram/milliliter), and IFN     (nanogram/milliliter) in serum 
measured by Luminex assay. (D) Total serum concentrations of Ig isotypes (IgA, IgE, IgG  1 ,  IgG 2a  , and IgM). (E) Ox-LDL  –  specifi  c IgM and IgG  1   antibodies  in 
serum. Data shown are the mean   ±   the SEM.   n   = 10  –  13 mice/group from 2 independent experiments. *, P   <   0.05; **, P   <   0.01; ***, P   <   0.001, Student  ’  s 
unpaired   t   test.   JEM VOL. 205, February 18, 2008  343
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  sST2 exacerbated atherosclerosis development 
  Previous studies in humans have demonstrated that increased 
sST2 is an adverse prognostic sign in cardiovascular patients 
(  14, 15  ). Although sST2 is a potentially useful biomarker in heart 
disease, its biological role in atherosclerosis remains unclear. 
To confi  rm that IL-33 mediates its antiatherosclerotic func-
tions through its receptor ST2, we treated ApoE      /      mice on 
high-fat diet with sST2 (an Fc fusion protein), which can neu-
tralize IL-33 activity by acting as a decoy receptor of ST2 (  12  ). 
Male ApoE      /      mice aged 6 wk were fed a high-fat diet for 
12 wk. During the last 6 wk, mice were injected i.p. twice per 
week with sST2 or normal IgG control (50   μ  g/injection). Mice 
were killed at the end of the treatment, and atherosclerotic lesion 
size was quantifi  ed in the aortic sinus. ApoE      /      mice treated 
Th2 cells facilitate IgG  1   and IgE synthesis. We also assessed 
levels of ox-LDL  –  specifi  c antibodies, as this is likely to be one 
of the most prevalent presumptive autoantigens present in 
ApoE      /      mice on a high-fat diet. The IL-33  –  treated mice 
produced more total IgA, IgE, and IgG  1  , but less IgG  2a  , than 
control mice, demonstrating a strong Th2 bias (  Fig. 3 D  ). 
  Importantly, IL-33  –  treated mice also produced signifi  cantly ele-
vated IgG  1   antibody to ox-LDL. Interestingly, IgM antibody 
to both native acetyl-LDL and ox-LDL were signifi  cantly in-
creased in IL-33  –  treated mice, despite similar total levels of 
IgM in both groups (  Fig. 3 E  ). Antibodies to ox-LDL of the 
IgG  2a  , IgA, and IgE isotypes were absent in both groups of 
mice, and all LDL-specifi  c antibodies were low or absent in 
PBS-treated mice. 
    Figure 4.     sST2 exacerbated atherosclerosis development in the aortic sinus and promoted Th1 response of ApoE       /       mice.  ApoE    /     mice  were 
treated with control IgG (open bars) or sST2 (fi  lled bars). (A) Plaque size (intimal area, millimeter  2  ) in the aortic sinus (  n   = 9  –  10). (B) Representative photo-
micrographs of hematoxylin and eosin  –  stained aortic sections. (C) Quantifi  cation of plaque content: F4/80  +   macrophages (percentage of total plaque 
area,   n   = 9  –  10), T cells (number of CD3  +   T  cells/millimeter 2 ,   n   = 9  –  10), SMCs (percentage of total plaque area,   n   = 9  –  10), and collagen (percentage of total 
plaque area,   n   = 9  –  10). (D) Representative photomicrographs of F4/80  +   macrophages (brown), CD3  +   T cells (brown),     -smooth muscle actin (brown), and 
collagen (blue) staining in plaques of ApoE     /     mice treated with IgG or sST2. (E) IFN     production (nanogram/milliliter) by lymph node cells restimulated 
with     CD3 and measured by ELISA (  n   = 9  –  10). IL-5 (F) and IFN     (G; picogram/milliliter) in serum determined by Luminex assay (  n   =  9 – 10).  *,  P   <   0.05; 
***, P   <   0.001, Student  ’  s unpaired   t   test. Bars: (B) 400     m; (D; F4/80  +   macrophages) 25     m; (D; CD3  +   T cells) 25     m; (D;     -smooth muscle actin) 100    m; 
(D; collagen) 100    m.   344 IL-33 REDUCES ATHEROSCLEROSIS IN MICE | Miller et al.
(22.0   ±   2.6 vs. 20.7   ±   2.4 mmol/liter), or triglyceride (1.4   ±   
0.2 vs. 1.7   ±   0.3 mmol/liter) were found. It is therefore unlikely 
that changes in lipoprotein levels account for the aggravation 
of lesion size by the treatment with sST2 in these mice. 
  Immunological analysis of the mice revealed a signifi  cant 
increase in IFN     production by lymph node cells in mice 
treated with sST2 (  Fig. 4 E  ). Levels of IL-4, -5, and -13 in cell 
culture supernatants were low or absent. In addition, a signifi  -
cant decrease in IL-5 (  Fig. 4 F  ) and a marked increase in IFN     
(  Fig. 4 G  ) were detected in serum of mice treated with sST2. 
Levels of other cytokines (IL-1    , -2, -4, -6, -10, -12[p70], -13, 
TNF    , and MCP-1) in serum were low or absent. Specifi  c 
antibodies against ox-LDL could not be detected in either 
sST2-treated or control IgG-treated mice. These results there-
fore confi  rm that IL-33 attenuated atherosclerosis via ST2 
with sST2 developed signifi  cantly larger atherosclerotic plaque 
in the aortic sinus compared with control IgG-treated mice 
(0.66   ±   0.05 vs. 0.35   ±   0.05 mm  2  ; P = 0.0015;   Fig. 4, A and B  ).   
However, this was not caused by increased immune cell infi  l-
tration, as the cellular composition of the lesions was similar 
between the two groups. The percentage of plaque area 
staining positive for F4/80  +   macrophages (45.3   ±   4.7 vs. 47.0   ±   
5.0%) and the number of lesion-associated CD3  +   T lympho-
cytes (5,936   ±   745 vs. 5,632   ±   344 cells/mm  2  ) was similar 
  between mice treated with sST2 or control IgG (  Fig. 4, C 
and D  ). SMC and collagen content did not diff  er between the 
two groups (29.1   ±   2.3 vs. 32.2   ±   3.9% and 26.2   ±   1.1 vs. 
25.6   ±   1.3%, respectively;   Fig. 4, C and D  ). Similar concentra-
tions of total serum cholesterol (16.4   ±   1.9 vs. 20.2   ±   3.1 mmol/
liter), HDL-c (2.8   ±   0.8 vs. 2.4   ±   0.3 mmol/liter), VLDL/LDL-c 
    Figure 5.     An anti  –  IL-5 mAb prevented the reduction in plaque size and the induction of ox-LDL antibodies in serum by IL-33.  ApoE    /     mice 
were treated with IL-33 (fi  lled bars) or IL-33/    IL-5 (striped bars). (A) Plaque size (intimal area, millimeter  2  ) in the aortic sinus (  n   = 5). (B) Representative 
photomicrographs of hematoxylin and eosin  –  stained aortic sections. (C) Quantifi  cation of plaque content: F4/80  +   macrophages (percentage of total 
plaque area,   n   = 5), T cells (number of CD3  +   T cells/ millimeter  2 ,   n   = 5), SMCs (percentage of total plaque area,   n   = 5), collagen (percentage of total plaque 
area,   n   = 5). (D) Representative photomicrographs of F4/80  +   macrophages (brown), CD3  +   T cells (brown),     -smooth muscle actin (brown), and collagen 
(blue) staining in plaques of ApoE     /     mice treated with IL-33 or IL-33/    IL-5. (E) Ox-LDL  –  specifi  c IgM antibodies in serum (  n   = 5). (F) IL-5 and -12 (pico-
gram/milliliter) in serum determined by ELISA (  n   = 5). *, P   <   0.05; **, P   <   0.01, Student  ’  s unpaired   t   test. Bars: (B) 400     m; (D; F4/80  +   macrophages) 
25     m; (D; CD3  +   T cells) 25     m; (D;     -smooth muscle actin) 100     m; (D; collagen) 100    m .    JEM VOL. 205, February 18, 2008  345
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    MATERIALS AND METHODS   
  Reagents.     The IL-33 and sST2-Fc fusion proteins were prepared as previously 
described (  27, 28  ). Control IgG-Fc (Sigma-Aldrich) and     IL-5 antibody 
(TRFK-5; Insight Bio) were obtained commercially. 
  Animals.     Male ApoE      /      mice on the C57BL/6 background (backcrossed 
10 times; Charles River Laboratories) were bred in-house in a pathogen-free 
facility, weaned at 6 wk of age, and fed an atherogenic diet ad libitum (0.15% 
cholesterol and 21% lard; Special Diet Services). At 12 wk, mice were ran-
domly grouped and injected i.p. twice per week for 6 wk with control PBS or 
murine IL-33 (1   μ  g/injection) or murine IL-33 (1   μ  g/injection), plus anti  –  IL-5 
antibody (TRFK-5; 15   μ  g/injection), control IgG, or sST2 (50   μ  g/injection) 
diluted in PBS. Mice were killed at 18 wk of age. C57BL/6 mice were 
purchased from Harlan. Experiments were performed according to United 
Kingdom Home Offi   ce guidelines. 
  Primary cell culture.     Human umbilical vein ECs and coronary artery SMCs 
were purchased from TCS Cellworks Botolph Claydon. Human saphenous 
vein (HSV) ECs and SMCs were prepared as previously described (  29  ). 
  Quantitative PCR.     RNA was extracted and purifi  ed using an RNeasy Micro 
kit (QIAGEN). mRNA expression was analyzed by quantitative PCR using 
SYBR GREEN PCR Master Mix and 18S rRNA (both from Applied 
Biosystems) as an endogenous control on the 7900HT RT-PCR system 
(Applied Biosystems). All primer sequences are available upon request. 
  Serum analysis.     Total serum cholesterol and triglyceride levels (millimole/
liter) were measured by enzymatic assay (Roche). HDL, VLDL, and LDL 
cholesterol distribution were measured using a BioVision kit, and therefore 
values do not exactly add up to the total cholesterol measurements. Serum Ig 
isotypes (IgE, IgA, IgG  1  , IgG  2a  , and IgM) were measured by ELISA (1:1,000 
sera dilution) and specifi  c antibody pairs (BD Biosciences). Copper oxida-
tion of LDL was performed as previously described (  25  ). To quantify ox-
LDL  –  specifi  c antibodies, plates were coated with 100   μ  g/ml native acetyl- or 
ox-LDL, washed, and blocked, and then sera were added at an optimized 1:50 
dilution and specifi  c detection antibodies  for IgA, IgE, IgG, IgG  2A , and IgM 
(BD Biosciences) were added. Serum cytokines were analyzed in an 11-plex 
mouse cytokine assay (Invitrogen). 
  Cytokine analysis.     Peripheral lymph nodes were removed, and single-cell 
suspensions were obtained by passing the cells through a 70-    m cell strainer. 
ST2 expression was examined by fl  ow cytometry using a FITC anti-ST2 anti-
body (MD Biosciences). Cells were stimulated in microwell cultures (2   ×   10  6  /
well) with plate-bound anti-CD3 (2.5   μ  g/ml; BD Biosciences) in RPMI 1640 
medium supplemented with 10% heat-inactivated FBS, 2 mM   l-  glutamine, 
100 U/ml penicillin, and 100   μ  g/ml streptomycin. Supernatants were col-
lected at 72 h and analyzed by ELISA for IL-4, -5, -13, -17, and IFN-     using 
paired antibody reagents (BD Biosciences/R  &  D Systems). For intracellular 
cytokine staining, cells were stimulated for 4 h with 50 ng/ml PMA (Sigma-
Aldrich) and 500 ng/ml ionomycin (Sigma-Aldrich) in the presence of 1 mg/ml 
Golgi-Plug (BD Biosciences). The cells were fi  xed, permeabilized, and stained 
with anti-CD4 and   –  IL-4,   –  IL-5, or -IFN     (BD Biosciences). 
  Atherosclerotic lesion analysis.     Atherosclerosis was quantifi  ed in the aortic 
sinus, as previously described (  30  ). In brief, the heart was sectioned parallel to the 
atria and sections were fi  xed, processed, and embedded in paraffi   n wax. 5 7-    m 
sections starting from the three valve cusps of the aortic sinus at 35-  μ  m intervals 
were cut and stained with hematoxylin and eosin for plaque area measurement 
in each mouse using Scion Image software (Scion Corporation). 
  Immunohistochemical staining was performed using the following mole-
cule-specifi  c and isotype-control antibodies as a negative control: anti-CD3 
(A0452; Dako) for T cells, anti-F4/80 (Clone CI:A3-1; Serotec) for macrophages, 
anti-smooth muscle actin (Clone 1A4; Sigma-Aldrich) for SMCs, anti-CD31 for 
ECs (BD Biosciences), and anti  –  IL-33 (R  &  D Systems). Staining was visualized 
using biotinylated secondary antibodies (Vector Laboratories) and detection 
signaling and highlight an sST2-mediated increase in IFN     
and atherosclerosis as a potential contributor to the adverse 
prognosis in cardiovascular patients with high sST2 in serum. 
  Anti  –  IL-5 mAb prevented the reduction in plaque size
and the induction of ox-LDL antibodies in serum by IL-33 
  To investigate the mechanism of the atheroprotective eff  ect of 
IL-33 further, we treated ApoE      /      mice on high-fat diet with 
either IL-33 alone (1   μ  g/injection) or IL-33 plus a neutralizing 
antibody to IL-5 (TRFK-5; 15   μ  g/injection) twice per week 
during the last 6 wk of high-fat diet. Coadministration of     IL-
5 plus IL-33 completely reversed the protective eff  ect of IL-33 
on plaque growth (0.14   ±   0.05 vs. 0.49   ±   0.1 mm  2  ; P = 0.0014; 
  Fig. 5, A and B  ).   Plaque phenotype was similar between the 
two groups (  Fig. 5, C and D  ), indicating that IL-5 was not re-
sponsible for the decreased macrophage and T cell infi  ltration 
seen with IL-33 when compared with PBS treatment. However, 
the induction of ox-LDL  –  specifi  c IgM antibodies was signifi  -
cantly reduced in the     IL-5  –  treated group (  Fig. 5 E  ). The levels 
of IL-5 in serum (  Fig. 5 F  ) were signifi  cantly lower, confi  rming 
neutralization by the     IL-5 antibody, with no eff  ect on other 
cytokines such as IL-12. Similar concentrations of total serum 
cholesterol (20.4   ±   1.4 vs. 23.2   ±   2.6 mmol/liter), HDL-c 
(2.1   ±   0.7 vs. 2.1   ±   0.1 mmol/liter), VLDL/LDL-c (18.4   ±   
2.2 vs. 20.9   ±   4.7 mmol/liter), or triglyceride (1.5   ±   0.1 vs. 
1.3   ±   0.2 mmol/liter) were found. It is therefore unlikely that 
changes in lipoprotein levels account for the larger lesion size 
induced by the treatment with     IL-5 plus IL-33 in these mice. 
  IL-5 is an important factor in the maturation and Ig-secre-
tion of B cells (  24  ), and IL-33  –  induced IL-5 secretion mediates 
the expansion of ox-LDL  –  specifi  c antibodies in these mice. 
Defi  ciency of IL-5 has been reported to reduce the production 
of atheroprotective antibodies and result in accelerated athero-
sclerosis in ApoE      /      mice (  11  ). Furthermore, antibodies spe-
cifi  c for ox-LDL inhibit macrophage uptake of ox-LDL, thus 
reducing foam cell formation (  25  ). In rabbit and murine mod-
els, it has been shown that immunization with ox-LDL induces 
antibody formation (both IgG and IgM) and protects against 
atherosclerosis development (  26  ). These studies, in addition to 
this study with IL-33, support a protective role of antibody-
mediated eff  ects on atherosclerosis and suggest that an IL-5  –
    induced anti –  ox-LDL antibody response is likely the mechanism 
by which IL-33 mediates it atheroprotective eff  ect. 
  This is the fi  rst study demonstrating a modulatory role for 
IL-33 in the infl  ammation of atherosclerosis. We observed 
a decrease in lesion size in the aortic sinus with IL-33 treat-
ment, in addition to an induction of Th2-mediated immu-
nity (IL-4/-5/-13), reduced Th1 responses (IFN    ), and an 
increase in ox-LDL  –  specifi  c antibodies. Furthermore, IL-33 
treatment decreased the numbers of plaque-associated macro-
phages and T cells infi  ltrating into the atherosclerotic lesions, 
suggesting a reduced infl  ammatory response to the accu-
mulating lipid in the vessel wall. In conclusion, our study 
suggests that induction of Th2-associated cytokines and ox-
LDL  –  specifi  c antibody responses by IL-33 may represent a 
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with the ABC/DAB system. Collagen was stained using Gomori  ’  s One-Step 
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  Statistical analysis.     All data are the mean   ±   the SEM. Statistical analysis was 
performed using unpaired Student  ’  s   t   tests with Prism Software (GraphPad). 
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